Genome BC | GenomeWeb

Genome BC

The partners are planning a joint research center at Providence Health Care's St. Paul's Hospital in Vancouver and a center of excellence in China.

The partnership is part of a broader agreement between Genome BC and Genomics England to share data and tools around cancer and rare and infectious diseases.

The team will employ reverse vaccinology coupled with high-throughput genomics approaches, such as RNA-seq, to deliver the new vaccines within four years.

The effort aims to revitalize the commercial fishery for Coho salmon, and is part of a broader investment by the Canadian government into genomics research.

The partners will work together on the diagnosis and treatment of cancer and rare and infectious diseases.

Genome BC plans to use the funding to develop genomic tools that natural resource companies can use to address their needs.

A retrospective analysis of patients' DNA will be performed to determine whether genetic information could have altered the drug dosage that patients were prescribed. 

One of four new research centers, the collaborative network will look to push genomic and cell therapy technologies into clinical trials. 

Five research teams from the University of British Columbia and Simon Fraser University will split the funding.

NEW YORK (GenomeWeb) – A new project spearheaded by Genome British Columbia and the BC Pharmacy Association (BCPhA) aims to assess whether pharmacists can drive adoption of genetic testing among doctors and help provide patients greater access to personalized medicine.

Pages

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.